Concepedia

Publication | Open Access

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

DOIFull Paper Access

105

Citations

26

References

2019

Year

Kim-Hien T. Dao, Jason Gotlib, Michael M.N. Deininger, Stephen T. Oh, Jörge E. Cortes, Robert H. Collins, E. Winton, Dana Parker, Hyun‐Jung Lee, Anna Reister,
Journal of Clinical Oncology

Abstract

Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring <i>CSF3R</i>-T618I were most likely to respond.

References

YearCitations

Page 1